Claims

1. Use of a potassium-competitive acid blocker (P-CAB) in the manufacture of a medicament for the treatment, prevention and/or reduction of gastro-esophageal reflux disease (GERD) symptoms in patients who are partial responders to a proton pump inhibitor (PPI).
2. The use according to claim 1, wherein the medicament is for the treatment, prevention and/or reduction of symptoms of non-erosive reflux disease (NERD) or erosive esophagitis (EE) of Grade A as defined by the Los Angeles (LA) Classification.
3. The use according to claim 1 or 2, wherein the medicament is for the treatment, prevention and/or reduction of symptoms of NERD.
4. The use according to claim 1 or 2, wherein the medicament is for the treatment, prevention and/or reduction of symptoms of EE of Grade A as defined by the LA Classification.
5. The use according to any preceding claim, wherein the P-CAB is selected from 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine (vonoprazan), revaprazan (YH1885), tegoprazan (RQ-4), 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methylcyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526), soroprazan (BY359), linaprazan (AZD0865), 8-benzyloxy-2-methyl-imidazo(1,2-a)pyridin-3-yl)acetonitrile (SCH 28080), or a salt thereof.
6. The use according to any preceding claim, wherein the PCAB is vonoprazan or a salt thereof.
7. The use according to claim 6, wherein the PCAB is vonoprazan fumarate.
8. The use according to any preceding claim wherein the dose of the P-CAB to be administered is 0.5 mg to 500 mg per day.
9. The use according to claim 8 wherein the dose of the P-CAB to be administered is 20 mg to 40 mg per day.
10. The use according to claim 9 wherein the dose of the P-CAB to be administered is selected from 20 or 40 mg per day.
11. The use according to any one of claims 1 to 10, wherein the PPI is selected from lansoprazole, pantoprazole, omeprazole and rabeprazole, or an optically active form thereof, or a salt thereof.
12. The use according to claim 11, wherein the PPI is dexlansoprazole or esomeprazole or a salt thereof.
13. The use according to claim 12, wherein the PPI is esomeprazole or a salt thereof.